{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:45:19Z","timestamp":1759693519409},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/jcp.0b013e318270e5c5","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T10:17:20Z","timestamp":1352197040000},"page":"767-772","source":"Crossref","is-referenced-by-count":16,"title":["Trajectories of Agouti-Related Protein and Leptin Levels During Antipsychotic-Associated Weight Gain in Patients With Schizophrenia"],"prefix":"10.1097","volume":"32","author":[{"given":"Stefan","family":"Ehrlich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia V.","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Theophil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebke","family":"Haag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Lautenschlager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/schbul\/sbm109","article-title":". Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.","volume":"34","author":"Kumra","year":"2008","journal-title":"Schizophr Bull"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":". Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":". Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","article-title":"Metabolic syndrome with the atypical antipsychotics.","volume":"17","author":"Pramyothin","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance.","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/14656566.7.8.1005","article-title":". Current schizophrenia drugs: efficacy and side effects.","volume":"7","author":"Krebs","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0091-3057(03)00042-X","article-title":". Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.","volume":"75","author":"Pouzet","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":". A parametric analysis of olanzapine-induced weight gain in female rats.","volume":"181","author":"Cooper","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/oby.2010.6","article-title":". Increased food intake and energy expenditure following administration of olanzapine to healthy men.","volume":"18","author":"Fountaine","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":". Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.","volume":"27","author":"Kluge","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pnpbp.2007.09.012","article-title":". Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.","volume":"32","author":"Cooper","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.jcp.0000177549.36585.29","article-title":". A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors.","volume":"25","author":"Roerig","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-244X-10-72","article-title":". The potential role of appetite in predicting weight changes during treatment with olanzapine.","volume":"10","author":"Case","year":"2010","journal-title":"BMC Psychiatry"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.physbeh.2006.01.034","article-title":"To eat or not to eat; regulation by the melanocortin system.","volume":"89","author":"Hillebrand","year":"2006","journal-title":"Physiol Behav"},{"key":"R15-6-20210128","first-page":"379","article-title":". Acute intracerebroventricular administration of either carboxyl-terminal or amino-terminal fragments of agouti-related peptide produces a long-term decrease in energy expenditure in rats.","volume":"12","author":"Goto","year":"2003","journal-title":"Int J Mol Med"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/00001756-200105080-00045","article-title":". Time course of short-term and long-term orexigenic effects of Agouti-related protein (86-132).","volume":"12","author":"Lu","year":"2001","journal-title":"Neuroreport"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/ng1197-273","article-title":". Overexpression of Agrt leads to obesity in transgenic mice.","volume":"17","author":"Graham","year":"1997","journal-title":"Nat Genet"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1210\/endo.139.10.6332","article-title":". A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo.","volume":"139","author":"Rossi","year":"1998","journal-title":"Endocrinology"},{"key":"R19-6-20210128","first-page":"164","article-title":"AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Molecular Endocrinology (Baltimore, Md).","volume":"15","author":"Nijenhuis","year":"2001","journal-title":""},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1006\/bbrc.1997.7200","article-title":". ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors.","volume":"237","author":"Fong","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":". Positional cloning of the mouse obese gene and its human homologue.","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0896-6273(00)81084-3","article-title":"From lesions to leptin: hypothalamic control of food intake and body weight.","volume":"22","author":"Elmquist","year":"1999","journal-title":"Neuron"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.mp.4001909","article-title":". The role of leptin in anorexia nervosa: clinical implications.","volume":"12","author":"Hebebrand","year":"2007","journal-title":"Mol Psychiatry"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0083-6729(05)71012-8","article-title":". Leptin: structure, function and biology.","volume":"71","author":"Zhang","year":"2005","journal-title":"Vitam Horm"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/43185","article-title":". Congenital leptin deficiency is associated with severe early-onset obesity in humans.","volume":"387","author":"Montague","year":"1997","journal-title":"Nature"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1126\/science.278.5335.135","article-title":". Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein.","volume":"278","author":"Ollmann","year":"1997","journal-title":"Science"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.2337\/diabetes.48.10.2028","article-title":". Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action.","volume":"48","author":"Ebihara","year":"1999","journal-title":"Diabetes"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1210\/endo.140.2.6491","article-title":"Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting.","volume":"140","author":"Mizuno","year":"1999","journal-title":"Endocrinology"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ajmg.a.20600","article-title":". Ala67Thr polymorphism in the Agouti-related peptide gene is associated with inherited leanness in humans.","volume":"126A","author":"Marks","year":"2004","journal-title":"Am J Med Genet A"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2265.2004.02056.x","article-title":". Plasma concentrations of alpha-MSH, AgRP and leptin in lean and obese men and their relationship to differing states of energy balance perturbation.","volume":"61","author":"Hoggard","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2826.2002.00825.x","article-title":". Plasma agouti-related protein level: a possible correlation with fasted and fed states in humans and rats.","volume":"14","author":"Shen","year":"2002","journal-title":"J Neuroendocrinol"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1210\/jc.2004-1124","article-title":". Circulating melanin-concentrating hormone, agouti-related protein, and alpha-melanocyte-stimulating hormone levels in relation to body composition: alterations in response to food deprivation and recombinant human leptin administration.","volume":"90","author":"Gavrila","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1017\/S0033291711000365","article-title":". Agouti-related protein in patients with acute and weight-restored anorexia nervosa.","volume":"41","author":"Merle","year":"2011","journal-title":"Psychol Med"},{"key":"R35-6-20210128","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1210\/jcem.86.5.7458","article-title":". Plasma levels of agouti-related protein are increased in obese men.","volume":"86","author":"Katsuki","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.ijo.0801083","article-title":". Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies.","volume":"24","author":"Flint","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.nut.2008.11.033","article-title":". Association between intestinal tight junction permeability and whole-body electrical resistance in healthy individuals: a hypothesis.","volume":"25","author":"Valentini","year":"2009","journal-title":"Nutrition"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.pnpbp.2009.03.007","article-title":". The role of leptin and cortisol in hyperactivity in patients with acute and weight-recovered anorexia nervosa.","volume":"33","author":"Ehrlich","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R41-6-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00702-008-0151-3","article-title":". Leptin and its associations with measures of psychopathology in patients with anorexia nervosa.","volume":"116","author":"Ehrlich","year":"2009","journal-title":"J Neural Transm"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/WNF.0b013e3181fa2a6f","article-title":". A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia.","volume":"33","author":"Venkatasubramanian","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"R43-6-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":". Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.npp.1300563","article-title":". Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.","volume":"30","author":"Haupt","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R45-6-20210128","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/oby.2008.277","article-title":". Adiposity and eating behaviors in patients under second generation antipsychotics.","volume":"16","author":"Blouin","year":"2008","journal-title":"Obesity (Silver Spring)"},{"key":"R46-6-20210128","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.","volume":"59","author":"Martins","year":"2010","journal-title":"Diabetes"},{"key":"R47-6-20210128","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":". Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation.","volume":"6","author":"Ferno","year":"2011","journal-title":"PLoS One"},{"key":"R48-6-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatmentpharmacological mechanisms.","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"R49-6-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"R50-6-20210128","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/00207450802336683","article-title":". Serotonin-induced region-specific responses of the arcuate and ventromedial hypothalamic nuclei.","volume":"120","author":"Jia","year":"2010","journal-title":"Int J Neurosci"},{"key":"R51-6-20210128","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1210\/endo.141.6.7462","article-title":". Agouti-related protein-like immunoreactivity: characterization of release from hypothalamic tissue and presence in serum.","volume":"141","author":"Li","year":"2000","journal-title":"Endocrinology"},{"key":"R52-6-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1101\/gad.11.5.593","article-title":". Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice.","volume":"11","author":"Shutter","year":"1997","journal-title":"Genes Dev"},{"key":"R53-6-20210128","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.physbeh.2009.02.044","article-title":"Liking and wanting food rewards: brain substrates and roles in eating disorders.","volume":"97","author":"Berridge","year":"2009","journal-title":"Physiol Behav"},{"key":"R54-6-20210128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/eat.20745","article-title":". Epigenetic dysregulation of dopaminergic genes in eating disorders.","volume":"43","author":"Frieling","year":"2010","journal-title":"Int J Eat Disord"},{"key":"R55-6-20210128","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00406-009-0092-3","article-title":". The 5-HTTLPR polymorphism, platelet serotonin transporter activity and platelet serotonin content in underweight and weight-recovered females with anorexia nervosa.","volume":"260","author":"Ehrlich","year":"2010","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R56-6-20210128","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-2008-1078749","article-title":". Platelet monoamine oxidase activity in underweight and weight-recovered females with anorexia nervosa.","volume":"41","author":"Ehrlich","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"R57-6-20210128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archpsyc.1985.01790290119020","article-title":"Prolonged pharmacologic activity of neuroleptics.","volume":"42","author":"Campbell","year":"1985","journal-title":"Arch Gen Psychiatry"},{"key":"R58-6-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"Kissling W, et al..","volume":"79","author":"Leucht","year":"2005","journal-title":"What does the PANSS mean Schizophr Res"},{"key":"R59-6-20210128","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.schres.2011.01.022","article-title":". The association between weight change and symptom reduction in the CATIE schizophrenia trial.","volume":"128","author":"Hermes","year":"2011","journal-title":"Schizophr Res"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318270e5c5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:00:23Z","timestamp":1620957623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201212000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318270e5c5","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}